The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Joanna Kapeleris 1,2, Arutha Kulasinghe 1,2, Majid E. Warkiani 3,4, Ian Vela 5,6, Liz Kenny 7, Kenneth O’Byrne 1,2,8 and Chamindie Punyadeera 1,2*

1 School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia, 2 Translational Research Institute, Brisbane, QLD, Australia, 3 School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, Australia, 4 Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 5 Department of Urology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia, 6 Australian Prostate Cancer Research Centre, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Princess Alexandra Hospital, Brisbane, QLD, Australia, 7 School of Medicine, University of Queensland, Royal Brisbane and Women’s Hospital, Central Integrated Regional Cancer Service, Queensland Health, Brisbane, QLD, Australia, 8 Princess Alexandra Hospital, Queensland Health, Brisbane, QLD, Australia

Lung cancer affects over 1.8 million people worldwide and is the leading cause of cancer related mortality globally. Currently, diagnosis of lung cancer involves a combination of imaging and invasive biopsies to confirm histopathology. Non-invasive diagnostic techniques under investigation include “liquid biopsies” through a simple blood draw to develop predictive and prognostic biomarkers. A better understanding of circulating tumor cell (CTC) dissemination mechanisms offers promising potential for the development of techniques to assist in the diagnosis of lung cancer. Enumeration and characterization of CTCs has the potential to act as a prognostic biomarker and to identify novel drug targets for a precision medicine approach to lung cancer care. This review will focus on the current status of CTCs and their potential diagnostic and prognostic utility in this setting.

Keywords: lung cancer, NSCLC, SCLC, Circulating tumor cells, liquid biopsy

INTRODUCTION

Lung cancer is the leading cause of cancer-related mortality among men and women worldwide (1). In 2012, the incidence was estimated at 1.8 million new cases, accounting for 12.9% of all new cancers diagnosed globally (2). There is an estimated 18% survival rate beyond 5 years for all stages combined, with poor outcomes largely due to late diagnosis (1, 3). The majority of patients present with locally advanced or metastatic disease, with ~20–30% of patients presenting with early stage disease (3, 4). Late diagnosis is a major underlying cause for this advanced disease presentation (5). The annual mortality rate for lung cancer is higher than for colon, breast, and prostate cancers combined (6). The majority of patients presenting with advanced stage at diagnosis contributes to this poor outcome (4).

There are two main types of lung cancers, small cell lung carcinoma (SCLC) and non-small cell carcinoma (NSCLC). NSCLC is the most common, accounting for 80% of cases (7). NSCLC has three main histological subtypes: adenocarcinoma, squamous cell (epidermoid) carcinoma, and large cell undifferentiated carcinoma. Adenocarcinoma accounts for ~40% of cases although is increasing in relative incidence, and usually starts in mucus secreting epithelial cells (167). The prognosis of NSCLC subtypes depends on the stage of the tumor and the treatment availability.
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers diagnosed annually and up to 25% of lung cancer deaths. SCLC is characterized by a more aggressive clinical phenotype than NSCLC with progression to metastatic disease earlier in the disease course (8).

SCLC and NSCLC arise from different cell types and demonstrate varying clinical features as shown in Table 1.

Lung cancer may be initiated through exposure to carcinogens. The main risk factor for lung cancer is the use of tobacco. Tobacco is known to initiate and promote carcinogenesis and accounts for 85% of lung cancer cases (9). Additional known risks include exposure to pollutants such as asbestos, tar and metals including arsenic, and chromium. Common symptoms include persistent cough, worsening breathing, pneumonia that fails to resolve, chest discomfort, wheezing, blood in the sputum, and hoarseness (3, 10). A minority are asymptomatic, detected by chance through investigation of other illnesses or in screening programs (11).

Treatment options depend on the intent of treatment and may include loco-regional treatment such as surgery, image guided ablation including radical chemo-radiotherapy, stereotactic ablative radiation treatment, thermal ablation or cryotherapy, or systemic treatment such as chemotherapy, targeted agents, and immunotherapy, alongside novel agents under current investigation in clinical trials (11). An example of the power of targeted therapies in a precision medicine approach was demonstrated in 2004 by Lynch et al. (12) and Paez et al. (13) who demonstrated that patients with EGFR mutations present in the tumors of patients with non-small cell lung cancer exhibited a dramatic response to gefitinib, the epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI), bringing personalized medicine to reality for a subset of NSCLC patients (12, 13).

Utilization of expensive systemic targeted therapies, however, has traditionally required invasive biopsies in order to assess for targetable tumoral aberrations. This presents a challenge for the monitoring of lung cancers due to the requirement for longitudinal sampling of tumors (14).

### TABLE 1 | Lung cancer classification.

| Location in the lung | Common features | Common mutations |
|----------------------|----------------|-----------------|
| NSCLC (80–85%)       | • Most common type of cancer in non-smokers • More common in women • Should test for EGFR, ALK, ROS1 and BRAF mutation for targeted therapy | • EGFR • KRAS • CDKN2A • ALK • BRAF • MET • TP53 |
| Adenocarcinoma (40%) | • Strongly associated with cigarette smoking • Similar characteristics to adenocarcinoma | |
| Squamous cell carcinoma (25-30%) |  | |
| Large cell carcinoma (10-15%) |  | |
| SCLC (15–20%)        | • Strongest association with smoking • Very rapid growth • Early distant metastasis in brain, liver and bone • Worst prognosis • Better response to chemotherapy | • MYC • BCL2 • c-KIT • TP53 • RB |

### METASTASIS AND EPITHELIAL-MESENCHYMAL TRANSITION

Metastasis is an extremely complex, multistep process. Cells must gain the ability to intravasate into the blood from the bulk tumor, travel through the blood undergoing sheer stressors and immune evasion, and extravasate to favorable metastatic sites such as bone, brain and liver (15–17). In order to detach from the primary tumor and disseminate into the blood, cells must undergo a cellular process known as epithelial-mesenchymal transition (EMT) (18). EMT enables tumor cells to become motile and enhances migratory capabilities which in effect allows cells to penetrate into the lymph vasculature and circulate as single or clusters of circulating tumor cells (CTCs) (19). Whilst in blood, CTCs exist in a dynamic EMT state (20). CTCs extravasate having undergone the reverse process known as mesenchymal to epithelial transition (MET) and colonize at distant organs, (21). EMT is thought to support cell invasiveness but restrict proliferation, thereby maintaining cancer cell survival in metastatic sites whereas MET re-activates proliferative potential (22). The famous “seed and soil” hypothesis proposed by Stephen Pagent in the Nineteenth century suggesting that tumor cells (the “seed”) have a preference to metastasize in certain organs (the ‘soil) (23). This hypothesis has since been revisited by Fidler and Langly, still holding significance in cancer research today (24, 25).
CIRCULATING TUMOR CELLS IN LUNG CANCER

CTCs were first described by an Australian physician, Thomas Ashworth in 1869, where cancer cells in the blood were observed which resembled the cells of the primary tumor (26). CTCs play a central role in the metastatic spread of lung cancer, that is ultimately responsible for patient morbidity and mortality from the disease (27). While the concept of CTCs were described over one hundred years ago, it is only recently that they have been utilized in cancer diagnosis and prognosis (28).

Evidence has shown that the presence of CTCs in the blood correlates with poor overall survival in patients with metastatic prostate, breast and colon cancers (29–31). Patients with SCLC have on average 10 times more CTCs than patients with any other tumor type (32–34).

Molecular targeted therapies such as tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutants and anaplastic lymphoma kinase (ALK) inhibitors in ALK rearranged NSCLC patients have recently advanced the management of lung cancer for a limited proportion of patients (35–39). To determine eligibility for such targeted therapies, tumor biopsies have traditionally been necessary, increasing the likelihood of biopsy-related complications (40). Even in patients developing resistance to first line EGFR TKIs, liquid biopsies using circulating tumor DNA plasma only detect T790M mutations in ~80% of cases, particularly in low volume disease, making a repeat biopsy necessary. Tumor heterogeneity within the primary site or between primary and metastatic sites, can also create potential sampling bias, which may mask the true genetic profile of the cancer. The prospect of longitudinal sampling in order to monitor for the development of therapeutic resistance to treatments is likewise limited if invasive biopsies are essential (41, 42).

Use of CTCs as a liquid biopsy is promising for serial assessment of tumor evolution during the course of the disease and during systemic treatment in a less invasive, real-time manner, by a simple blood draw (19, 43). This liquid biopsy also provides potential for the early diagnosis of cancer and valuable insights into tumor heterogeneity and genomic diversity for the early diagnosis of cancer and guidance of clinical treatment (44, 45). A sensitive and unbiased isolation method to capture CTCs is therefore essential to provide tumoral material for analysis and potentially drive treatment decisions (46, 47).

CIRCULATING TUMOR CELL DETECTION METHODS IN LUNG CANCER

CTCs have the potential to accompany standard screening tests and be used for molecular characterization of a tumor (48). Detection of CTCs in NSCLC has been challenging due to the rarity in circulation (a few CTCs per billion normal blood cells) and the presence of non-epithelial characteristics (49). It is therefore imperative that sensitive and specific CTC detection methods are developed and optimized to assist in better patient monitoring and management (50–54). The advantages and disadvantages of the isolation methods in lung cancer are discussed and summarized in the Table 2. A summary of the CTC lung cancer studies are highlighted in Table 3.

EX-VIVO EXPANSION OF CIRCULATING TUMOR CELLS

Despite limitations of current CTC isolation techniques, these cells have been detected in a number of cancers, including breast, head, and neck cancer, lung, prostate, colon and gastric cancer (21, 50, 53, 109, 132–135). Successful ex-vivo culture of CTCs represents a “Holy Grail” in the study of cancer metastasis as it allows for in depth characterization of metastasis initiating cells as well as the testing of functional assays (136).

Short-term CTC culture (3–14 days) has been achieved in a number of cancer types, even from early stage cancers (137–139). This allows for the recapitulation of the disease in an ex vivo/in vivo setting for the testing of therapies and functional analysis (140). A summary of this is in Table 4. In comparison, long-term cultures have only been established in advanced metastatic cases where a large number of CTCs have been isolated (111, 142, 143) (Table 5). Long-term culture studies have shown that some CTCs in patient blood are immortalized and can be cultured ex vivo into stable cell lines (Figure 1) (139). There are only a few reports of successful long-term culture, notably, in patients with advanced stages of disease (136, 145, 146). CTC-expansion has been limited due to the influence of CTC enrichment. Certain cancers also require specific culture conditions for primary and metastatic samples (136). The successful culture of CTCs long-term holds great promise in developing personalized cancer treatment for testing of therapeutic efficacy using drug screening (140). This approach could assist in determining the choice of therapeutic regimen beneficial for patients and hence holds significance in advancement of precision medicine and personalized oncology (139).

Three main strategies are used for the propagation of CTCs in culture; two-dimensional (2D) culture, very commonly used for expansion of CTCs short-term, three-dimensional (3D) culture used for long-term expansion and xenotransplantation and four dimensional (4D) shown to mimic the process of metastasis (137, 147–150).

The expansion of CTCs in-vivo to generate patient derived xenografts (PDXs) may also be used to comprehensively analyse advanced disease biology and present a valuable model to understand cancer metastasis. The use of PDXs have been shown to mimic patient’s disease and mirror response to chemotherapy (e.g., Platinum agents) (142, 151). However, PDXs have been challenging due to CTC heterogeneity causing unreliability of these models to translate clinically. PDX model development also takes 4–8 months and therefore are not optimal for rapid studies necessary for patients with advanced disease (151). In an ideal world cancer cell lines would be routinely generated from each cancer patient but this is not realistic at present (136, 139, 152).

CLINICAL SIGNIFICANCE

The immediate need for early detection of lung cancer recurrence and monitoring treatment response is essential to facilitate ...
TABLE 2 | The Summary of different Circulating Tumor Cell isolation methods currently used in research.

| Isolation method          | Mode of action                                                                 | Advantages                                                                                                                                  | Disadvantages                                                                 | Examples                                      |
|---------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------|
| FDA approved (clinical trials) | EpCAM positive based selection | Has become the “gold standard” for validation of CTCs with an epithelial phenotype. High reproducibility. High specificity. FDA-approved method. | CTCs can undergo EMT which may result in reduced expression of epithelial markers, leading to loss of effective capturing of cells with mesenchymal characteristics following EMT. | Cellsearch (Menarini Silicon Biosystems, Italy) |
| Positive Immunoselection  | EpCAM positive based selection | Ability to process larger volumes of blood for the capture of higher numbers of CTCs.                                                     | As above                                                                      | GILUPI CellCollector (GILUPI Nanomedizin) (55) Ephesia CTC-chip (56) |
| Negative Immunoselection  | Depletion of Leukocytes by CD45 Antibodies | Has the ability to avoid false-negative results or loss of CTCs due to phenotypic heterogeneity.                                           | CTCs are often contaminated with remaining blood cells resulting in low purity. | RosetteSep (StemCell Technologies, Canada) (57) EPISPOT (Epithelial Immunospot Assay, France) (58) |
| Size-Based Filtration     | Cells are separated using filtration to remove smaller cells in the blood (e.g., White blood cells) | Simple process.                                                                  | Will exclude small sized CTCs, filter clogging and limited blood processing/filter are potential problems. | Screen Cell (France) Metasell (Ostrava, Czech Republic) Isolation by Size of Epithelial Tumor cells (SSET, Rarecells Diagnostics, Paris, France) (59) Microdevice- Cote’s group (60) Parsortix (61) Microcavity array System (MCA) (62) |
| Density-based Filtration  | Cells are separated based on different densities after centrifugation.      | Cells separated into distinct layers                                              | CTC size and density not uniform                                             | Ficoll Lymphoprep (Stem Cell Technologies, Vancouver, Canada) (63) OncoQuick (W.R, Radnor,PA) Accucyte (64) |
| Microfluidics             | Cells are separated based on their biological or physical properties | Higher sensitivity, purity, lower cost, reduced sample size, short processing time, compatibility with downstream assays | Small CTCs of comparable size to WBCs would typically be missed | Isoflux (Fuxion Biosciences) (65) CTC Chip (Nagrath) (66, 67) ClearCell FX/Spiral Microfluidics (ClearbridgeBiomedics, Singapore) (64) Herringbone Chip (Nagrath) (31) |
| Immunomagnetic            | Enriches target cells and eliminates cells that are not bound to magnetic particles | Isolate cells easily accessible                                                    | Nonspecific contamination can be from adsorption of background cells to the capturing device | MagSweeper (Jeffrey Lab,Stanford, CA) (68) AdnaTest (Qiagen, Hannover, Germany) (69) Magnetic Activated Cell Sorting System (Mitenyi Biotec, Germany) (70, 71) MagSifter (72) |
| Electrophoresis           | Cells are separated based on their electrical signature using an electric field | Single-cell-level precision High accuracy and precision                           | Process can be slow resulting in low sample throughput                      | DEPAArray (Silicon Biosystems) |
| Enrichment free platforms | Cells are detected through imaging platforms with no need for enrichment due to advancements in fluorescence imaging | Multiple analysis parameters can be used to identify and characterize specific populations of interest High specificity and sensitivity. No need for enrichment. | Potential for high speed imaging to reduce resolution thereby worsening accuracy. | HD-CTC (EPIC Sciences, California) (44, 73, 74) FastCell (SRI Biosciences) (75) CytoTrack (Denmark) (76, 77) |

improved survival of patients. Previous studies have shown computerized tomography (CT) screening has helped to reduce mortality, however CT has risks such as radiation exposure, leading to an increased risk of long-term cancer (153). This signifies the need for less invasive techniques for the early detection of metastasis and aid the personalized treatment of lung cancer. The use of CTCs as a liquid biopsy has the potential to accompany standard screening tests and also allow for molecular and genetic characterization of the tumor (48).

Enumeration of CTCs could provide a biomarker for cancer surveillance following treatment of early, locally advanced and advanced lung cancer and provided a better understanding on the mechanisms of metastasis (33). Although chemotherapy, targeted small molecules and immune checkpoint inhibitor
TABLE 3 | Summary of a number of Circulating Tumor Cell studies in lung cancer.

| Study                  | Histology | Sample number | Isolation method | Major findings                                                                 | References |
|------------------------|-----------|---------------|------------------|---------------------------------------------------------------------------------|------------|
| Das et al., 2012       | NSCLC     | 57            | FastCell         | CTCs were detected in 42% of patients.                                          | (78)       |
| Devriese et al., 2012  | NSCLC     | 46            | Cellsearch       | CTCs were detected in 62% of patients. 30% of patients positive for CK7 and 9% positive for CK19. | (79)       |
| Hiltermann et al., 2012| SCLC      | 59            | Cellsearch       | Lower number of CTCs in patients with early stage SCLC. CTC decrease after one cycle of chemotherapy- no change after four cycles | (80)       |
| Hirose et al., 2012    | NSCLC     | 33            | Cellsearch       | CTCs were detected in 96.4% of patients and 15.2% had five or more CTCs before chemotherapy. No difference in response to chemotherapy between CTC-positive and CTC-negative patients. Progressive disease higher in CTC-positive patients. | (81)       |
| Hofman et al., 2012    | NSCLC     | 250           | ISET             | CNHC’s were detected in 49% of patients corresponding to malignant (41%), uncertain malignant (6%) and benign cells (2%) respectively. | (82)       |
| Hou et al., 2012       | SCLC      | 97            | Cellsearch       | CTCs present in 85% of patients. OS of 5.4mths for ≥50 CTCs/7.5ml blood           | (83)       |
| Ilie et al., 2012      | NSCLC     | 87            | ISET             | CTCs positive for ALK from 5 patients corresponded to patients having ALK-rearrangement in tumors. | (84)       |
| Isole et al., 2012     | NSCLC     | 24            | Cellsearch       | CTCs detected in 33.3% of patients                                              | (85)       |
| Krebs et al., 2012     | NSCLC     | 45            | Cellsearch/ISE T | CTCs detected in 80% of patients using ISET compared to 23% of patients using Cellsearch. Subpopulation of cells detected by ISET did not express epithelial markers | (86)       |
| Naito et al., 2012     | SCLC      | 51            | Cellsearch       | Patients with ≥8 had worse survival than those with <8 CTCs.                    | (87)       |
| Punnoose et al., 2012  | NSCLC     | 41            | Cellsearch       | CTCs were detected in 78% of patients at baseline. High baseline CTC counts associated with response to treatment. Decreased CTCs associated with PFS. | (88)       |
| Saucedo-Zeni et al., 2012 | NSCLC   | 24            | GILUPI CellCollector | CTCs were successfully enriched from over 90% of patients with breast cancer or non-small cell lung cancer. | (89)       |
| Wendel et al., 2012    | NSCLC     | 78            | HD-CTC assay     | CTCs were detected in 73% of patients. No significant difference between stages. | (90)       |
| Funaki et al., 2013    | NSCLC     | 130           | Rosette Sep      | ITCs were detected in 74% of patients.                                          | (91)       |
| Hosokawa et al., 2013  | NSCLC     | 22            | MCA              | CTCs were detected in 77% of patients using the MCA system versus 32% using the Cellsearch system. MCA system also isolated CTC clusters from patients identified as CTC-negative using Cellsearch. | (92)       |
| Ni et al., 2013        | NSCLC and SCLC | 11      | Cellsearch       | Copy number variations reported from single CTCs similar to that of the metastatic tumor of the same patient. | (93)       |
| Pailer et al., 2013    | NSCLC     | 18            | Cellsearch/ISET  | ALK rearrangements detected in CTCs of patients with ALK positive NSCLC enabling monitoring and testing of crizotinib. | (94)       |
| Swennenhuis et al., 2013 | NSCLC   and SCLC | 10   | Cellsearch       | CTCs from 25% of patients were identified and single CTCs were isolated and amplified. | (95)       |
| Carlsson et al., 2014  | NSCLC     | 129           | HD-CTC assay     | Presence of CTM combined with clinical and imaging data assisted in discriminating for diagnostic accuracy in all NSCLC patients. | (96)       |
| Earhart et al., 2014   | NSCLC     | 6             | Magnetic Sifter  | CTCs detected in 100% of patients.                                              | (97)       |
| Ilie et al., 2014      | NSCLC     | 168           | ISET             | CTCs were detected in 3% of COPD patients                                        | (98)       |
| Juan et al., 2014      | NSCLC     | 37            | Cellsearch/ISET  | ALK rearrangements detected in CTCs of patients with ALK positive NSCLC enabling monitoring and testing of crizotinib. | (99)       |
| Marchetti et al., 2014 | NSCLC     | 37            | Cellsearch       | CTCs were detected in 41% of patients. EGFR mutations identified by NGS in 84% of patients. | (100)      |
| Muinelo-Romay et al., 2014 | NSCLC   | 43            | Cellsearch       | At baseline 41.9% of patients were positive for CTCs. Patients with ≥5 baseline had worse PFS and OS. Patients with increased levels of CTCs has worse PFS and OS. | (101)      |

(Continued)
TABLE 3 | Continued

| Study             | Histology | Sample number | Isolation method         | Major findings                                                                                                                                   | References |
|-------------------|-----------|---------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Nel et al., 2014  | NSCLC     | 43            | Negative depletion       | Increased CD133-positive to pan-CK-positive cell type ratio (stem like to epithelial ratio) and presence of mesenchymal N-cad-positive cells, associated with shorter PFS. | (101)      |
| Normanno et al., 2014 | SCLC     | 60            | Cellsearch              | At baseline 90% of patients were positive for CTCs and strongly associated with organs involved. CTC reduction as high as 89% following chemotherapy. | (102)      |
| Chudsama et al., 2015 | NSCLC   | 20            | Screen Cell             | An increase in CTCs following EC observed in 75% of patients. Could have implications for tumor dissemination and metastatic spread.         | (103)      |
| Dorsey et al., 2015 | NSCLC   | 23            | Density gradient centrifugation | CTCs positive in 65% of patients. CTC count reflect clinical course and response to treatment.                                           | (104)      |
| Tu et al., 2015   | NSCLC and SCLC | 18 | Cellsearch              | CSFTC were positive in 78% of MRI confirmed LM samples. CSFTC clusters were observed in 67% of patients.                                 | (105)      |
| Aieta et al., 2016 | NSCLC    | 1             | Cellsearch              | Presence of EML4-ALK+ CTCs at baseline. EML4-ALK+ CTCs could be interpreted as resistance sign to crizotinib treatment leading to progressive disease. | (106)      |
| Cheng et al., 2016 | SCLC    | 89            | Cellsearch              | CTCs positive in 87.6% of patients. CTC count independent indicator for PFS and OS.                                                            | (107)      |
| Crosbie et al., 2016 | NSCLC   | 27            | Cellsearch              | CTCs positive in 22% of patients at baseline. CTC detection at baseline associated with reduced DFS and 3-year survival.                   | (108)      |
| Hanssen et al., 2016 | NSCLC   | 48            | Cellsearch              | CTCs positive in 15% of patients. CTC positivity was associated with patient disease state.                                                   | (109)      |
| He et al., 2016   | NSCLC     | 66            | Cellsearch              | Presence of CTCs associated with significantly shorter PFS.                                                                                   | (110)      |
| Morrow et al., 2016 | NSCLC    | 1             | Cellsearch              | CDX derived from CTCs enriched from NSCLC patient.                                                                                             | (111)      |
| Nicolazzo et al., 2016 | NSCLC   | 24            | Cellsearch              | Patients with PD-L1 negative CTCs all had clinical benefit, while patients with PD-L1 (+) CTCs all experienced progressive disease.       | (112)      |
| Tan et al., 2016  | NSCLC     | 27            | ClearCell FX            | CTCs positive in 100% of patients, 14 were ALK-positive.                                                                                     | (113)      |
| Zhang et al., 2016 | NSCLC    | 46            | Negative immunoselection | CTCs positive in 87% of patients. CTC count of more than eight prior to chemotherapy was a strong predictor of PFS.                    | (114)      |
| Chudsama et al., 2017 | NSCLC   | 10            | ScreenCell              | A significant increase in CTCs was observed from baseline levels following lung manipulation.                                                   | (115)      |
| Chudsama et al., 2017 | NSCLC   | 23            | ScreenCell              | CTCs positive in 78.3% and 73.9% reviewed by 2 pathologists.                                                                                  | (116)      |
| Coco et al., 2017 | NSCLC     | 73            | ScreenCell/ISET         | Baseline CTC count had no significant association with OS or PFS.                                                                               | (117)      |
| Ilie et al., 2017 | NSCLC     | 39            | Cellsearch/ISET         | CTCs positive in 32% of patients evaluated on Cellsearch. CTCs positive in 75% of patients evaluated on ISET. Expression of MET was positive in 72% of cases. | (118)      |
| Lindsay et al., 2017 | NSCLC   | 125           | Cellsearch              | CTCs positive in 40.8% of patients. Patients with ≥2 CTCs at baseline had poorer prognosis.                                                     | (119)      |
| Messaritakis et al., 2017 | SCLC   | 64            | Cellsearch              | CTCs positive in 50% of patients before treatment. Pazopanib treatment significantly reduced proportion of patients with increased CTC numbers. High CTC number at baseline correlated with reduced PFS and OS. Detection of VEGFR2+ CTCs during treatment could be associated with resistance to pazopanib. | (120)      |
| Messaritakis et al., 2017 | SCLC   | 108           | Cellsearch              | CTCs positive in 60.2% of patients at baseline. Presence of proliferative (CK8+/+) and non-proliferative (Ki67-), apoptotic (M30+) and non-apoptotic (M30-) as well as EMT (Vim+) CTCs were present in the same patient. | (121)      |
| Paller et al., 2017 | NSCLC    | 39            | Cellsearch/ISET         | Significant association between the decrease in CTC number with ALK-CNG on crizotinib and longer PFS. ALK-CNG may be a predictive biomarker for crizotinib efficacy in ALK-rearranged NSCLC patients. | (122)      |
| Salgia et al., 2017 | SCLC     | 42            | Cellsearch              | CTCs positive in 83% of patients at baseline. Presence of CTCs at baseline were prognostic of shorter PFS and OS.                           | (123)      |
### TABLE 3 | Continued

| Study               | Histology | Sample number | Isolation method          | Major findings                                                                                                                                                                                                 | References |
|---------------------|-----------|---------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Tong et al., 2017   | NSCLC     | 127           | Negative immunoselection  | CTCs positive in 80.31% of patients at baseline. Patients with post-treatment increases in CTC count had poorer OS and PFS than those without increases. Baseline CTC count and change in CTC count during treatment were valuable prognostic indicators for NSCLC. | (124)      |
| Wang et al., 2017   | SCLC      | 42            | Negative immunomagnetic enrichment | CTCs positive in 76.19% of patients with SCLC and negative in controls. PFS correlates with CTC numbers and the change in CTC numbers after 1 cycle of chemotherapy.                          | (125)      |
| Yang et al., 2017   | NSCLC     | 107           | Cellsearch               | CTCs positive in 44% of patients at baseline. CTC >5 at baseline was a strong negative predictor of PFS and TTF. Five or more CTCs on day 28 were strongly associated with a poor PFS. | (126)      |
| Yuanling et al., 2017 | NSCLC    | 105           | Cellsearch               | CTCs positive (≥2) in 29% of patients at baseline and 9% had ≥5 CTCs. CTC count of ≥5 CTCs correlated with poor PFS and OS.                                                                                       | (127)      |
| Alamgeer et al., 2018 | SCLC    | 28            | Cellsearch               | At baseline, two or more CTCs were detected in 86.6% of patients.                                                                                                                                               | (128)      |
| Guibert et al., 2018 | NSCLC    | 96            | ISET                      | CTCs positive in 93% of patients at baseline. CTCs more frequently PD-L1+ than tissue (83 vs. 41%). Pre-treatment high CTC counts associated with increased risk of death and progression. Pre-treatment PD-L1+CTCs associated with bad prognosis in patients treated with PD-1 inhibitors. | (129)      |
| Milano et al., 2018 | NSCLC     | 10            | Density gradient centrifugation | CTCs undergoing EMT (CTCsEMT) positive in 30% of patients. CTCsEMT detection related to poor therapeutic response.                                                                                       | (130)      |
| Tong et al., 2018   | NSCLC     | 43            | Negative immunoselection  | CTCs positive in 76.7% of patients at baseline. CTC count was a strong predictor of PFS and OS.                                                                                                                 | (131)      |

NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CTC, circulating tumor cells; CNHCs, circulating non-hematological cells; ITC, isolated tumor cells; CTM, circulating tumor microemboli; OS, overall survival; PFS, progression-free survival; TTF, time-to-treatment failure; COPD, chronic obstructive pulmonary disease; EC, endobronchial cryotherapy; CSFTC, cerebrospinal fluid tumor cell; MRI, Magnetic Resonance Imaging; LM, leptomeningeal metastasis; NGS, next-generation sequencing; CDX, cell line-derived xenograft.

### TABLE 4 | Summary of short-term Circulating Tumor Cell culture in Lung cancer.

| Study           | Method of CTC isolation | CTC culture conditions                                                                 | Group size | Morphology | Reference |
|-----------------|-------------------------|----------------------------------------------------------------------------------------|------------|------------|-----------|
| Zhang et al., 2014 | in situ capture and culture | 4 Culture Conditions: 1. 3D co: Collagen, matrigel and cancer associated fibroblasts from pancreatic tumor 2. 3D mono: Only gel culture 3. 2D co: Only cancer associated fibroblasts 4. 2D mono: No gel or fibroblasts | 14         | Spheroids  | (141)     |

Therapies have shown significant benefits, the occurrence of acquired drug resistance and disease relapse are very common. Through serial sampling a longitudinal analysis of CTCs for identification of tumor evolution could provide valuable insights into mechanisms underlying resistance (154).

Detection of CTCs in lung cancer has been challenging, as CTCs usually present with non-epithelial characteristics (49). This emphasizes the need for more sensitive technologies to better capture CTCs for in-depth characterization and functional studies using cell culture and xenograft models. This will then ultimately assist in optimizing personalized therapies for lung cancer patients, with CTCs potentially being a prognostic biomarker.

### CONCLUSION

The clinical significance of CTCs is yet to be established, however, advances in CTC detection and single-cell profiling have significantly improved our knowledge of underlying mechanisms of the evolution and dissemination of cancer and is progressively being translated to clinical studies. With lung cancer being the largest cause of cancer mortality worldwide, one of the biggest challenges for managing and treating patients is the lack of early screening/diagnostic methods (4). The isolation of CTCs from cerebrospinal fluid (CSF), may represent a unique subpopulation CTCs with ability to survive the journey in blood circulation and subsequent invasion of the CNS (105, 155). CTCs hold great promise as biomarkers for the early diagnosis and treatment.
TABLE 5 | Summary of long-term Circulating Tumor Cell culture in Lung cancer.

| Study            | Histology | Method of CTC isolation | CTC culture conditions | Group size | CTC lines established | Morphology/Histology | References |
|------------------|-----------|-------------------------|------------------------|------------|-----------------------|----------------------|------------|
| Hodgkinson et al., 2014 | SCLC      | RosetteSep/Ficol/ xenotransplantation | Xenotransplantation    | 6          |                       | Morphology of CDX macrometastases: 1. Clusters 2. Sheets of densely packed small round or oval cells 3. Scant cytoplasm 4. Enlarged/inconspicuous nuclei 5. Speckled chromatin 6. Focal nuclear molding | (142)     |
| Hamilton et al., 2015 | SCLC      | Ficoll-Hypaque           | RPMI 1640 medium, serum-free (insulin, IGF-1, selenite) | 30         | 3                     | Spheroids or attached | (143)     |
| Morrow et al., 2016 | NSCLC     | RosetteSep/Ficol/ xenotransplantation | Xenotransplantation    | 1          |                       | Morphology of CDX macrometastases: 1. Diffuse sheets of large polygonal cells 2. Abundant eosinophilic cytoplasm 3. Vesicular chromatin 4. Enlarged nucleoli | (111)     |
| Drapkin et al., 2018 | SCLC      | RosetteSep/Ficol/ xenotransplantation | Xenotransplantation    | 46         |                       | Cytoplasmic expressions of chromogranin, synaptophysin and/or CD56 as well as the lack of CD45 expression confirmed diagnosis | (144)     |

FIGURE 1 | Culture of circulating tumor cells.

Selection of patients as well as broadening the current knowledge of metastasis (154).

Recurrence and progress of the disease, severity of symptoms and side-effects dramatically decrease patient’s quality of life (QoL) (156). Therefore there is a vital need to monitor tumor evolution and understand mechanisms underlying development of therapeutic resistance.

Challenges for the field to address include the low sensitivity and specificity of current technologies prohibiting their use in current clinical settings, the large number of CTCs required for the development of CTC lines and patient xenografts for downstream functional analyses and the limited number of CTCs frequently found in patients with early stage disease (157). CTCs have demonstrated prognostic clinical utility is breast, lung and prostate cancers using the CellSearch technology (158, 159). Recent studies have demonstrated renewed interest in the FDA-approved Cellsearch platform for CTC PD-L1 analysis (160–162). These studies demonstrate how CTCs could be used to identify patients for anti PD-1/PD-L1 therapy (immunotherapy). Cellsearch relies on CTC enrichment using EpCAM (when CTCs undergo EMT, EpCAM is downregulated). As such the field is moving toward label-free technologies for CTC isolation. Currently, there are a number of technologies to enrich CTCs (i.e., RareCyte, iChip, ISET, DEPArray, EPISPOT etc). The current label-free technologies are being validated for a number of cancers in larger clinical trials (163, 164). This is highlighted by the Cancer-ID network consortium in standardizing CTC/ctDNA and exosome isolation, analysis and reporting (165). The current gold standard in isolating CTCs from patient blood relies on the EpCAM status of these cells, thereby excluding a large majority of CTCs present in the blood of metastatic patients. Furthermore, Cellsearch does not allow for subsequent culture as the cells are fixed (166). CTCs as a liquid biopsy have valuable potential to improve early diagnosis, monitoring of
disease, and direct treatment of lung cancer, however a better understanding of CTC biology is crucial for the field to move forward.

**AUTHOR CONTRIBUTIONS**

JK, AK, KO, CP: Idea. JK, AK, MW: Preparation of figures and tables. All authors were involved in the preparation, review and editing of the manuscript.

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. (2017) 67:6–30. doi: 10.3322/caac.21387

2. Wong MCS, Lao XQ, Ho K-F, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. (2017) 7:14300. doi: 10.1038/s41598-017-14513-7

3. Institute NNC. Cancer Stat Facts: Lung and Bronchosus Cancer [Online]. NIH-National Cancer Institute (2017). Available online at: https://seer.cancer.gov/statfacts/html/ lungbh.html (Accessed July 17, 2017).

4. Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. J Thorac Dis. (2011) 3:183–8. doi: 10.3978/j.issn.2072-1439.2011.01.01

5. Birring SS, Peake MD. Symptoms and the early diagnosis of lung cancer. Thorax (2005) 60:268. doi: 10.1136/thx.2004.026989

6. Malik PS, Raina V. Lung cancer: prevalent trends & emerging concepts. Indian J Med Res. (2015) 141:5–7.

7. Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. (2011) 32:703–40. doi: 10.1016/j.ccm.2011.08.003

8. Australia CC. Lung Cancer [Online]. (2017). Available online at: http://www.cancer.org.au/about-cancer/types-of-cancer/lung-cancer.html#jump_1.0.0.1

9. Dela Cruz GS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. (2011). 32: 605–44. doi: 10.1016/j.ccm.2011.09.001

10. Cooley ME. Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage (2000) 19:137–53. doi: 10.1016/S0885-3924(99)00150-5

11. Institute NNC. Lung Cancer [Online]. (2017). Available online at: https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq (Accessed July 17, 2017).

12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. (2004) 350:2129–39. doi: 10.1056/NEJMoa040938

13. Paetz JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497. doi: 10.1126/science.1099314

14. Hansen A, Loges S, Pantel K, Wikman H. Detection of circulating tumor cells in non-small cell lung cancer. Front Oncol. (2015) 5:207. doi: 10.3389/fonc.2015.00207

15. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. (2000) 19:1–XI, 193–383.

16. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Pax6. Cancer Cell (2009) 16:98–101.

17. Maheswaran S, Fidler IJ. The pathogenesis of cancer metastasis: theseed and soil hypothesis revisited. Nat Rev Cancer (2003) 3:453. doi: 10.1038/nrc1098

18. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 2:442–54. doi: 10.1038/nrc6222

19. Nurwidy F, Zaini J, Putra AC, Andarini S, Hudoyo A, Syahrudin E, et al. Circulating tumor cell and cell-free circulating tumor DNA in lung cancer. Chonnam Med J. (2016) 52:151–8. doi: 10.4068/cmj.2016.52.3.151

20. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 339:580–4. doi: 10.1126/science.1228552

21. Kulasinghe A, Kenny L, Perry C, Thiery J-P, Ivanovic L, Vela I, et al. Impact of label-free technologies in head and neck cancer circulating tumor cells. Oncotarget (2016) 7:71223–34. doi: 10.18632/oncotarget.12086.

22. Ocaña OH, Cóceres R, Fabra Á, Moreno-Bueno G, Acolque H, Vega S, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Pax6. Cancer Cell (2012) 22, 709–724. doi: 10.1016/j.cccr.2012.10.012

23. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. (1989) 8:98–101.

24. Cristofanilli, M, Budd, GT, Ellis, MJ, Stopeck, A, Matera, J, Miller, MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. (2004) 351:781–91. doi: 10.1056/NEJMoa040766

25. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. (2009) 10:233–9. doi: 10.1016/S1470-2045(08)70340-1

26. Tanaka F, Yoneda K, Hasegawa S. Circulating tumor cells (CTCs) in lung cancer: clinical implications. J Thorac Dis. (2017) 9 (Suppl 8):S791–8.

27. Alix-Panabieres C, Pantel K. Characterization of single circulating tumor cells. J Thorac Dis. (2017) 9 (Suppl 8):S779–85.

28. Hong Y, Fang F, Zhang Q. Circulating tumor cell clusters: what we know and what we expect (Review). Int J Oncol. (2016) 49:2206–16. doi: 10.3892/ijio.2016.3747

29. Mooney K, Hasegawa S. Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives. Lung Cancer (2010) 1:77–84.

30. Krebs MG, Sloane P, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. (2011) 29:1536–63. doi: 10.1200/JCO.2010.28.7045

31. Alix-Panabieres C, Pantel K. Characterization of single circulating tumor cells. F1000 Res. (2016) 5:2241–50. doi: 10.12688/f1000research.7362.1

32. Rosell R, Vassilakopulos P, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. EORTC trial 22011 versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer. Cancer Cell (2017) 33:712–23. doi: 10.1016/j.ccr.2017.08.013

33. Wu Y, Wust P, Herweijer H, Janne PA, Blackhall FH, Kamel RG, et al. Improved survival with crizotinib in advanced ALK-positive non-small-cell lung cancer. N Engl J Med. (2013) 369:2365–75. doi: 10.1056/NEJMoa1306745

34. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. EORTC trial 22011 versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer.

ACKNOWLEDGMENTS

The authors would like to thank Mr. Sadegh Ghorbani for assisting in the schematic. This study was supported by the Queensland Centre for Head and Neck funded by Atlantic Philanthropies, the Queensland Government and the Translational Research Institute (TRI) Spore grant. QUT VC Fellowship for CP. QUT postgraduate research scholarship for JK.
51. Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells: advances

56. Saliba A-E, Saias L, Psychari E, Minc N, Simon D, Bidard F-C, et al. Microfluidic sorting and multimodal typing of cancer cells in self-microfluidics. *J Cell Biol.* (2015) 220:167–76. doi: 10.1016/j.jcb.2015.10.004

58. Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. *Recent Results Cancer Res.* (2012) 195:69–76. doi: 10.1007/978-3-642-28160-0_6

59. Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. *Clin Cancer Res.* (2011) 17:827–35. doi: 10.1158/1078-0432.CCR-10-0445

60. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. *Clin Cancer Res.* (2010) 16:5601–8. doi: 10.1158/1078-0432.ccr-10-1105

61. Obermayr E, Maritschegge E, Speiser P, Singer C, Schuster EM, Danzinger S, et al. Circulating rare cells enable highly efficient cancer detection. *Cancer Res.* (2013) 73(15 Suppl.). doi: 10.1158/1332-4488.tc2013-197

62. Hosokawa M, Yoshihata T, Negishi R, Yoshino T, Koy Y, Kenmotsu H, et al. Microcytosis array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. *Anat Chem.* (2013) 85:5692–8. doi: 10.1021/ac400167x

63. Weitz J, Kienle P, Lacroix I, Willeke F, Benner A, Lehnert T, et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. *Clin Cancer Res.* (1998) 4:343–8.

64. Campton DE, Ramirez AB, Nordberg JI, Drovetto N, Klein AC, Varshavskaya P, et al. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. *BMC Cancer.* (2015) 15:360. doi: 10.1186/s12885-015-1383-x

65. Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, et al. Mutation analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. *Transl Oncol.* (2013) 6:528–38. doi: 10.1016/j.tranon.2013.06.003

66. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irini D, Ulkus L, et al. Isolation of rare circulating tumor cells in cancer patients by microchip technology. *Nature* (2007) 450:1235–9. doi: 10.1038/nature06385

67. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. *J Thorac Oncol.* (2009) 4:281–3. doi: 10.1097/JTO.0b013e3181989565

68. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh K-H, Yu W, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. *Proc Natl Acad Sci USA.* (2009) 106:3970–5. doi: 10.1073/pnas.0813188106

69. Zieglschmid V, Hoffmann C, Gutierrez B, Albert W, Strothoff D, Gross E, et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. *Anticancer Res.* (2005) 25:1803–10.

70. Millenky S, Muller W, Weichel W, Raddusch A. High gradient magnetic cell separation with MACS. *Cytometry* (1990) 11:231–8. doi: 10.1002/cyto.99010203

71. Mayo C, Ortega EA, Giménez-Capitán A, Molina-Vila MA, Serrano MJ, Viteri S, et al. Combination of immunomagnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. *Transl Lung Cancer Res.* (2013) 2:65–71. doi: 10.3978/j.issn.2218-6751.2013.02.06

72. Earhart CM, Hughes CE, Gaster RS, Ooi CC, Wilson RJ, Zhou LY, et al. Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. *Lab Chip.* (2014) 14:78–88. doi: 10.1039/c3lc50580d

73. Bazenova L, Nieva JJ, Koltak A, Lutgten M, Marinucci D, Bethel K, et al. Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with small-cell lung cancer (NSCLC). *J Clin Oncol.* (2013) 30(15_suppl):e21074. doi: 10.1200/jco.2012.30.15_suppl.e21074

74. Marinucci D, Bethel K, Koltak A, Lutgten MS, Malchiodzi M, Baehring F, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. *Phys Biol.* (2012) 9:016003. doi: 10.1088/1478-3967/9/1/016003

75. Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergord DE, et al. A rare-cell detector for cancer. *Proc Natl Acad Sci USA.* (2004) 101:10501–4. doi: 10.1073/pnas.0404036101

76. Hillig T, Horn P, Nygaard AB, Haugaard AS, Nejlund S, Brandslund I, et al. In vitro detection of circulating tumor cells compared by the
Circulating tumor cells (CTCs) are a promising tool for predicting and monitoring the course of many types of cancer. The detection of circulating tumor cells (CTCs) in patients with non-small-cell lung cancer (NSCLC) has been linked to a poor prognosis. The review of literature shows that the number of circulating tumor cells (CTCs) is significantly correlated with the progression-free survival (PFS) of patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. The evaluation of circulating tumor cells and related events as prognostic factors in patients with non-small cell lung cancer undergoing surgery for non-small cell lung carcinoma using the isolation by size cytometry (ISET) method. The significance of tumour vessel invasion in determining the morphology of patients with non-small cell lung cancer. The role of circulating tumor cell composition in patients with non-small cell lung cancer. The efficiency of whole genome amplification of single circulating tumor cells (ctg) using a novel detection technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. A real-time liquid biopsy for treatment.
111. Morrow CJ, Trapani F, Metcalfe RL, Bertolini G, Hodgkinson CL, Khandelwal G, et al. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study. *Ann Oncol.* (2016) 27:1155–60. doi: 10.1093/annonc/mdw122

112. Nicolazzo C, Raimondi M, Cancini M, Caponnetto S, Gradilone A, Gandini O, et al. Monitoring PD-L1-positive circulating tumour cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. *Sci Rep.* (2016) 6:31726. doi: 10.1038/srep31726

113. Tan CL, Lim TH, Lim TKH, Tan DS-W, Chua YW, Ang MK, et al. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. *Oncotarget* (2016) 7:23251–62. doi: 10.18632/oncotarget.8136

114. Zhang Z, Xiao Y, Zhao J, Chen M, Xu Y, Zhong W, et al. Relationship between circulating tumour count and prognosis following chemotherapy in patients with advanced non-small cell lung cancer. *Respirology* (2016) 21:519–25. doi: 10.1111/resp.12696

115. Chudasama D, Burnsside N, Beeson J, Karteris E, Rice A, Anvin K. Perioperative detection of circulating tumour cells in patients with lung cancer. *Oncol Lett.* (2017) 14:1281–6. doi: 10.3892/ol.2017.6366

116. Chudasama D, Barr J, Beeson J, Beddow E, Mcgonigle N, Rice A, et al. Detection of circulating tumour cells and survival of patients with non-small cell lung cancer. *Anticancer Res.* (2017) 37:169–73. doi: 10.21873/anticancer.11302

117. Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, et al. Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy. *Int J Mol Sci.* (2017) 18:1035. doi: 10.3390/ijms18051035

118. Ilie M, Szafar-Blusman I, Hofman V, Long-Mira E, Suttmann R, Darbonne E, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. *Nat Biotechnol.* (2013) 31:539–44. doi: 10.1038/nbt.2576

119. Kulasinghe A, Perry C, Warkiani ME, Blick T, Davies A, O’Byrne K, et al. Short term ex-vivo expansion of circulating head and neck tumour cells. *Oncotarget* (2016) 7:60101–9. doi: 10.18632/oncotarget.11159

120. Kulasinghe A, Tran TH, Blick T, O’Byrne K, Thompson EW, Warkiani ME, et al. Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. *Sci Rep.* (2017) 7:42517. doi: 10.1038/srep42517

121. Maheswaran S, Haber DA. *Ex Vivo Culture of CTCs: an emerging resource to guide cancer therapy.* *Cancer Res.* (2015) 75:2411–5. doi: 10.1158/0008-5472.CAN-15-0145

122. Guo D, Vela I, Stoner A, Izumiya P, Karthaus WR, Gopalani A, et al. Organoid cultures derived from patients with advanced prostate cancer. *Cell* (2014) 159:176–87. doi: 10.1016/j.cell.2014.08.016

123. Alich-Panabieres C, Bartkowiak K, Pantel K. Functional studies on circulating and disseminated tumor cells in carcinoma patients. *Mol Oncol.* (2016) 10:44–9. doi: 10.1016/j.molonc.2016.01.004

124. Gao D, Vela I, Stoner A, Izumiya P, Karthaus WR, Gopalani A, et al. Organoid cultures derived from patients with advanced prostate cancer. *Cell* (2014) 159:176–87. doi: 10.1016/j.cell.2014.08.016

125. Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. *Cancer Discov.* 8:600–15. doi: 10.1158/2159-8290.CD-17-0935

126. Wang R, Chu GCC, Mordenic S, Annamalai AA, Hendiñaf AE, Nissen NN, et al. Cultured circulating tumor cells and their derived xenografts for personalized oncology. *Asian J Urol.* (2016) 3:2420–53. doi: 10.1016/j.ajur.2016.08.005

127. Qi Y, Wang W. Clinical significance of circulating tumor cells in squamous cell lung cancer patients. *Cancer Biomark* (2017) 18:161–7. doi: 10.3237/cbm-160090

128. Alamgeer M, Neil Watkins D, Banak I, Kumar B, Gough DJ, Markman B, et al. A phase Ia study of HA-1: HA-targeted, formulation of hyaluronic acid and irinotecan taro targets CD44 in extensive-stage small cell lung cancer. *Invest New Drugs* (2018) 36:288–98. doi: 10.1007/s10637-017-0555-8

129. Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. *Lung Cancer* (2018) 120:108–12. doi: 10.1016/j.lungcan.2018.04.001

130. Milano A, Mazzafera F, Valente S, Ranieri D, Leone L, Botticelli A, et al. Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients: potential role in clinical practice. *Anat Cell Pathol.* (2018) 2018:3506874. doi: 10.1155/2018/3506874

131. Wang R, Chu GCC, Mordenic S, Annamalai AA, Hendiñaf AE, Nissen NN, et al. Cultured circulating tumor cells and their derived xenografts for personalized oncology. *Asian J Urol.* (2016) 3:2420–53. doi: 10.1016/j.ajur.2016.08.005

132. Khoo BL, Grcen G, Jing T, Lim YB, Lee SC, Thiery JP, et al. Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. *Sci Adv.* (2016) 2:e1600274. doi: 10.1126/sciadv.1600274

133. Zhang Z, Shiratsuchi H, Lin J, Chen G, Reddy RM, Azizi E, et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. *Oncotarget* (2014) 5:12383–97. doi: 10.18632/oncotarget.2592

134. Hodgkinson CL, Morrow CJ, Li Y, Metcalfe RL, Rothwell DG, Trapani F, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. *Nat Med.* (2014) 20:897–903. doi: 10.1038/nm.3600

135. Hamilton G, Burghuber O, Zeillinger R. Circulating tumor cells in patients undergoing chemotherapy. *Oncotarget* (2017) 8:86615–24. doi: 10.18632/oncotarget.21255

136. Wang YL, Liu CH, Li J, Ma XP, Gong P. Clinical significance of circulating tumor cells in patients with small-cell lung cancer. *Tumori J.* (2017) 103:242–8. doi: 10.3301/tjm.600601

137. Qi Y, Wang W. Clinical significance of circulating tumor cells in squamous cell lung cancer patients. *Cancer Biomark* (2017) 18:161–7. doi: 10.3237/cbm-160090

138. Alamgeer M, Neil Watkins D, Banak I, Kumar B, Gough DJ, Markman B, et al. A phase Ia study of HA-1: HA-targeted, formulation of hyaluronic acid and irinotecan taro targets CD44 in extensive-stage small cell lung cancer. *Invest New Drugs* (2018) 36:288–98. doi: 10.1007/s10637-017-0555-8
146. Pantel K, Alix-Panabieres C. Functional studies on viable circulating tumor cells. *Clin Chem.* (2016) 62:328–34. doi: 10.1373/clinchem.2015.242537

147. Khoj BL, Lee SC, Kumar P, Tan TZ, Warikani ME, Ow SG, et al. Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. *OncoTarget* (2015) 6:15578–93. doi: 10.18632/oncotarget.3903

148. Kolostova K, Spicka J, Markowski R, Bobek V. Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers. *Am J Transl Res.* (2015) 7:1203–13.

149. Mishra DK, Creighton CJ, Zhang Y, Chen F, Thrall MJ, Kim MP. Ex vivo.

150. Mishra DK, Miller RA, Pence KA, Kim MP. Small cell and non small cell lung cancer form metastasis on cellular 4D lung model. *BMC Cancer* (2018) 18:441. doi: 10.1186/s12885-018-4358-s

151. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discov.* (2014) 4:998–1013. doi: 10.1158/2155-8290.CD-14-0001

152. Dive C, Brady G. Snapshot: circulating tumor cells. *Cell* (2017) 168:742.e741. doi: 10.1016/j.cell.2017.01.026

153. Albert JM. Radiation risk from CT: implications for cancer screening. *Am J Roentgenol.* (2013) 201:W81–7. doi: 10.2214/AJR.12.9226

154. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. *Nat Rev Clin Oncol.* (2014) 11:129–44. doi: 10.1038/nrclinonc.2013.253

155. Faltas B. Circulating tumor cells in the cerebrospinal fluid: “tapping” into diagnostic and predictive potential. *OncoTarget* (2011) 2:822. doi: 10.18632/oncotarget.349

156. Polanski J, Jankowska-Polanska B, Rosinczuk J, Chabowski M, Szymanska-Chabowska A. Quality of life of patients with lung cancer. *Onco Targets Ther.* (2016) 9:1023–8. doi: 10.2147/OTT.S100685

157. Man Y, Wang Q, and Kemmer W. Currently used markers for CTC isolation - advantages, limitations and impact on cancer prognosis. *J Clin Exp Path.* (2011) 1:102. doi: 10.4172/2166-0881.1000102

158. Allard WJ, Mataro J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res.* (2004) 10:8897–904. doi: 10.1158/1078-0432.cc-04-0378

159. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. *J Natl Cancer Inst.* (2018) 110:560–7. doi: 10.1093/jnci/djy018

160. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topath D, Cayrefourcq L, et al. Frequent expression of PD-L1 on circulating breast cancer cells. *Mol Oncol.* (2015) 9:1773–82. doi: 10.1016/j.molonc.2015.05.009

161. Kulasinghe A, Perry C, Kenny L, Warikani ME, Nelson C, Punyadeera C. PD-L1 expressing circulating tumour cells in head and neck cancers. *BMC Cancer* (2017) 17:333. doi: 10.1186/s12885-017-3316-3

162. Strati A, Koutsodontis G, Paxapinios G, Angelidis I, Zavridou M, Economopoulou P, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. *Ann Oncol.* (2017) 28:1923–33. doi: 10.1093/annonc/mdx206

163. Pinzani P, Salvadori B, Simi L, Bianchi S, Distante V, Cataliotti L, et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. *Hum Pathol.* (2006) 37:711–8. doi: 10.1016/j.humpath.2006.01.026

164. Kaifi JT, Kunkel M, Das A, Harouaka RA, Dicker DT, Li G, et al. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. *Cancer Biol Ther.* (2015) 16:699–708. doi: 10.1080/15384047.2015.1030556

165. Schlange T, Stockecklin N, Neves RP, Pleier S, Bender S, Brychta N, et al. Abstract 513: Standardization of technologies for CTC, ctDNA and miRNA enrichment, isolation and analysis for liquid biopsies during the first year of IMI’s CANCER-ID. *Cancer Res.* (2016) 76:513. doi: 10.1158/1538-7445.AM2016-513

166. Neumann MH, Schneck H, Decker Y, Schomer S, Franken A, Endris V, et al. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch(R) system and the CellCelector(). *Biotechnol Prog.* (2017) 33:125–32. doi: 10.1002/btpr.2294

167. American Cancer Society [Online]. Available online at: https://www.cancer.org/cancer/non-small-cell-lung-cancer.html (Accessed October 11, 2017).

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Kapeleris, Kulasinghe, Warikani, Vela, Kenny, O’Byrne and Punyadeera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*